Skip to main navigation Skip to search Skip to main content

Phase I study of dalteparin in combination with sunitinib as first-line treatment in patients with metastatic renal cell carcinoma

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
JournalJournal of clinical oncology
Volume32
Issue numbersuppl abstr e15607
Publication statusPublished - 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this